Results 51 to 60 of about 2,692 (128)

KOH 5% solution versus diclofenac 3% for the treatment of actinic keratosis – Results from a three‐armed RCT

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 6, Page 1050-1058, June 2026.
In this RCT, KOH 5% demonstrated superior clinical success to diclofenac 3% and placebo at the end of treatment in patients with mild‐to‐moderate actinic keratosis and comparable long‐term efficacy to diclofenac. Its fast onset of efficacy and favourable tolerability make KOH a valuable treatment option in early‐stage actinic keratosis treatment ...
U. Reinhold   +18 more
wiley   +1 more source

Non-adherence to topical treatments for actinic keratosis

open access: yes, 2013
Bav Shergill,1 Simon Zokaie,2 Alison J Carr3 1Department of Dermatology, Brighton and Sussex University Hospitals, Elm Grove, Brighton, UK; 2Leo Pharma, Princes Risborough, 3Hamell, London, UK Background: There is limited information on the patterns of ...
Shergill B, Zokaie S, Carr AJ
core  

Hundred Most Cited Articles in Actinic Keratosis: A Bibliometric Analysis

open access: yes
Many articles have been published on actinic keratosis. Bibliometric analysis helps identify the most influential studies in a particular field, Our article was to identify the 100 most frequently cited references on actinic keratosis through ...
Zuoyao Qi   +3 more
core   +1 more source

AI‐assisted basal cell carcinoma diagnosis with LC‐OCT: A multicentric retrospective study

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 6, Page 1059-1068, June 2026.
Real‐time AI assistance significantly improves dermatologists' performance in diagnosing basal cell carcinoma with LC‐OCT, outperforming traditional imaging methods. AI‐assisted novices reached expert‐level performance, bridging a 2‐year expertise gap, thus supporting a broader clinical adoption of non‐invasive technologies, reducing the need for ...
Sébastien Fischman   +64 more
wiley   +1 more source

Ingenol mebutate in low amounts for the treatment of actinic keratosis in Korean patients

open access: yes, 2017
Hyun Jae Joe, Byung Ho Oh Department of Dermatology, Keimyung University, College of Medicine, Daegu, Republic of Korea Background: Ingenol mebutate (IM), a novel agent for field therapy of actinic keratosis (AK), has a drawback of inducing local skin ...
Joe HJ, Oh BH
core  

Actinic Keratosis Pathogenesis Update and New Patents

open access: yes, 2016
Background Actinic keratosis is a common premalignant skin lesion. Because of increasing incidence of actinic keratosis, several efforts have been done to detect earlier this premalignant lesion and to improve knowledge on photocarcinogenic pathways of ...
CANTISANI, CARMEN   +7 more
core  

Dermoscopy of actinic keratosis, intraepidermal carcinoma and squamous cell carcinoma

open access: yes, 2014
In the realm of keratinocyte skin cancer, specific dermoscopic patterns that are associated with different stages of progression have been identified, which allows for an improved clinical diagnosis and differentiation actinic keratosis, intraepidermal ...
Giuseppe Argenziano   +3 more
core   +1 more source

Optimal treatment of actinic keratosis

open access: yes, 2013
Gary GoldenbergMount Sinai School of Medicine, New York, NY, USAWe read with interest the review by Uhlenhake on treatments for actinic keratosis (AK).1 The author presents a summary of the various AK treatment options used to reduce the risk of ...
Goldenberg G
core  

A Long‐Standing Palmar Depressed Macule

open access: yes
JEADV Clinical Practice, Volume 5, Issue 2, Page 734-736, June 2026.
Jhon Edwin Rodríguez‐Vásquez   +4 more
wiley   +1 more source

Serum Levels of Lipid Fractions in Actinic Keratosis

open access: yes, 2000
Amaç: Aktinik keratozis malign bir hastalıktır, güneşin indüklediği deri hasarının önemli bir belirtisidir. Bu çalışmanın amacı aktinik keratozis ve serum lipid seviyeleri arasında bir ilişkinin olup olmadığını göstermekti. Yöntem: Aktinik keratozisli 20
Balevi, Şükrü
core  

Home - About - Disclaimer - Privacy